Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EPS (Basic): 2013-2024

Historic EPS (Basic) for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$0.59.

  • ImmunityBio's EPS (Basic) rose 41.67% to -$0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.39, marking a year-over-year increase of 56.67%. This contributed to the annual value of -$0.59 for FY2024, which is 48.70% up from last year.
  • ImmunityBio's EPS (Basic) amounted to -$0.59 in FY2024, which was up 48.70% from -$1.15 recorded in FY2023.
  • In the past 5 years, ImmunityBio's EPS (Basic) registered a high of -$0.59 during FY2020, and its lowest value of -$1.15 during FY2023.
  • In the last 3 years, ImmunityBio's EPS (Basic) had a median value of -$1.04 in 2022 and averaged -$0.93.
  • As far as peak fluctuations go, ImmunityBio's EPS (Basic) slumped by 50.85% in 2021, and later soared by 48.70% in 2024.
  • ImmunityBio's EPS (Basic) (Yearly) stood at -$0.59 in 2020, then tumbled by 50.85% to -$0.89 in 2021, then dropped by 16.85% to -$1.04 in 2022, then fell by 10.58% to -$1.15 in 2023, then soared by 48.70% to -$0.59 in 2024.